The WHO antimicrobial resistance survey for 2026, released on November 16 ahead of World AMR Awareness Week (November 18 to 24), finds that 173 of 183 responding countries now have a national action plan against antimicrobial resistance (AMR), more than double the 79 that had one in 2017. The catch: only 42 countries say their plan is both financed and being implemented, and the world remains off track for the 2030 targets governments agreed at the UN General Assembly in 2024.
Key takeaways on the WHO antimicrobial resistance survey
- 173 of 183 countries have a national AMR action plan, but just 42 (about 22%) report that it is funded and implemented.
- About 1 in 6 laboratory-confirmed bacterial infections worldwide is now resistant to antibiotics.
- Only 66 countries can test for both bacterial and fungal resistance, far from the goal of 80% of countries by 2030.
- 113 countries track antibiotic use and 109 track resistance, but only 21 link the two datasets.
- Infection prevention programmes run nationwide in only 69 countries (38%), against a 2030 target of 90%.
The scorecard in numbers
The annual Tracking AMR Country Self-assessment Survey (TrACSS) is run jointly by WHO, the UN Environment Programme, the World Organisation for Animal Health and the Food and Agriculture Organization. This year’s responses cover 94% of WHO member states. The table pulls together the main indicators reported by Reuters and WHO’s release.
| Indicator | 2026 | Earlier figure or target |
|---|---|---|
| National AMR action plan in place | 173 countries | 79 in 2017 |
| Plan financed and implemented | 42 countries | No earlier figure given |
| National infection prevention programme and guidelines | 128 countries | 90 in 2018 |
| Infection prevention implemented nationwide | 69 countries (38%) | Target 90% by 2030 |
| Reference lab for common bacterial resistance | 131 countries | n/a |
| Bacterial and fungal resistance testing | 66 countries (36%) | Target 80% by 2030 |
| Monitoring antibiotic use | 113 countries | 65 in 2017 |
| Monitoring resistance levels | 109 countries | 39 in 2017 |
| Integrating use and resistance data | 21 countries | n/a |
By our calculation, the share of countries with a plan has risen from about 43% to 95% of respondents since 2017, while fewer than one in four can show that the plan is actually paid for and running.
Why funding, not paperwork, is the bottleneck
Writing a plan is cheap; staffing laboratories, training hospital infection-control teams and running surveillance systems is not. WHO Director-General Tedros Adhanom Ghebreyesus framed the plans as essential for protecting the medicines that protect us, but the survey shows that in most countries those plans lack dedicated budgets. WHO’s acting AMR director, Jean Pierre Nyemazi, warned that routine procedures become much riskier when antimicrobials stop working, and that new antibiotic development is not keeping pace. If trends continue, drug-resistant infections could contribute to more than 39 million deaths worldwide over the next 25 years.
The laboratory gap
Resistance cannot be managed if it cannot be measured. While 131 countries have a national reference laboratory able to test common bacteria, only 66 can also test fungi, and WHO says just 36% have labs equipped for selected bacterial and fungal pathogens. To help close the gap, WHO’s AMR Diagnostic Initiative has released two tools: a prioritised catalogue of essential diagnostic tests and step-by-step procedures for clinical laboratories. The weakest link is integration: only 21 countries combine antibiotic-use data with resistance data, which is the analysis that shows how prescribing drives resistance.
What it means for India
India is one of the countries with a current plan. Union Health Minister J P Nadda launched the National Action Plan on AMR 2.0 on November 18, 2025, covering 2025 to 2029. It succeeds the 2017 to 2021 plan and assigns ministry-specific action plans, a budget and cross-sector coordination across human health, animal husbandry, environment and research. Priorities named at launch include curbing antibiotic misuse and overuse, expanding laboratory capacity and strengthening infection control in hospitals.
The global findings point to where India’s plan will be tested: whether each ministry publishes and funds its implementation roadmap, whether district hospitals gain fungal as well as bacterial testing, and whether antibiotic sales data can be tied to resistance surveillance. Country-level TrACSS answers for India were not detailed in the summaries released this week. Quality of supply matters too; see our reports on the pressure on penicillin manufacturing and the recent vancomycin recall, and more in Healthcare Services.
Market context
Commercial incentives for new antibiotics remain weak, which is one reason the pipeline lags. Acumen Research and Consulting projected the antibiotic resistance treatment market to reach about US$12.11 billion by 2026, at a CAGR of over 5.5% from 2018 to 2026. That report dates from December 2018, so the figure is indicative only, but it illustrates how small the market is relative to the public health burden.
What to watch during AMR Awareness Week
The 2026 campaign theme is One Health, one action: Prevent AMR now, linking human, animal, plant and environmental health. Watch for new national funding pledges, updates to country roadmaps, including India’s ministry-level plans, and progress reports against the 2030 targets on infection prevention and laboratory capacity.
Frequently asked questions
What is antimicrobial resistance?
AMR happens when bacteria, viruses, fungi or parasites change so that medicines no longer kill them or stop their growth. Infections then become harder to treat and more likely to spread or turn severe.
How many countries have an AMR action plan in 2026?
173 of the 183 countries that answered WHO’s 2026 survey have a national AMR plan, but only 42 say it is financed and implemented.
What is India’s National Action Plan on AMR 2.0?
It is India’s second national AMR plan, covering 2025 to 2029, launched in November 2025. It sets out roles and budgets for each ministry and focuses on reducing antibiotic misuse, improving laboratories and strengthening infection control.
What can individuals do to slow antibiotic resistance?
Use antibiotics only when prescribed by a qualified clinician, follow the instructions you are given, do not share leftover medicines, keep vaccinations up to date and practise good hand hygiene. Antibiotics do not work against viral illnesses such as colds and flu.
Sources: WHO TrACSS 2026 findings as reported by Reuters and WHO (November 16 to 17, 2026); Down To Earth on India’s NAP-AMR 2.0. Market data: Acumen Research and Consulting, Antibiotic Resistance Market report. This article is for information only and is not medical advice. Last updated November 17, 2026.

[…] survey showed that most countries have AMR action plans but few fund them, as we reported in our WHO antimicrobial resistance survey coverage. The ministry also cited the G20 New Delhi Leaders’ Declaration, which called for a […]